Mariana Mendonça Soares

Ms. Mariana Mendonça Soares

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2024 in Cells
Verified
Journal Article
Open access
PDF file
DFDavi Azevedo Ferreira
Davi Azevedo Ferreira
AMAnna Beatriz Araujo Medeiros
Anna Beatriz Araujo Medeiros
MSMariana Mendonça Soares
Mariana Mendonça Soares
ÉLÉssia de Almeida Lima
Éssia de Almeida Lima
GOGabriela Carolina Santos Lima de Oliveira
Gabriela Carolina Santos Lima de Oliveira
SRSandra Rodrigues-Mascarenhas
Sandra Rodrigues-Mascarenhas
Cardiotonic steroids are known to bind to Na+/K+-ATPase and regulate several biological processes, including the immune response. The synthetic cardiotonic steroid γ-Benzylidene Digoxin 8 (BD-8) is emerging as a promising immunomodulatory molecule, although it has remained largely unexplored. Therefore, we tested the immunomodulatory potential of BD-8 both in vitro and in vivo. Hence, primary mouse macrophages were incubated with combinations of BD-8 and the pro-inflammatory fungal protein zymosan (ZYM). Nitric oxide (NO) production was determined by Griess reagent and cytokines production was assessed by enzyme-linked immunosorbent assay. Inducible nitric oxide synthase (iNOS), reactive oxygen species (ROS), p-nuclear factor kappa B p65 (NF-κB p65), p-extracellular signal-regulated kinase (p-ERK), and p-p38 were evaluated by flow cytometry. Macrophages exposed to BD-8 displayed reduced phagocytic activity, NO levels, and production of the proinflammatory cytokine IL-1β induced by ZYM. Furthermore, BD-8 diminished the expression of iNOS and phosphorylation of NF-κB p65, ERK, and p38. Additionally, BD-8 exhibited anti-inflammatory capacity in vivo in a carrageenan-induced mouse paw edema model. Taken together, these findings demonstrate the anti-inflammatory activity of BD-8 and further reinforce the potential of cardiotonic steroids and their derivatives as immunomodulatory molecules.

Verified
Journal Article
Open access
PDF file
LCLuiz Henrique Agra Cavalcante-Silva
Luiz Henrique Agra Cavalcante-Silva
JSJosé Marreiro de Sales-Neto
José Marreiro de Sales-Neto
MSMariana Mendonça Soares
Mariana Mendonça Soares
DFDavi Azevedo Ferreira
Davi Azevedo Ferreira
AMAnna Beatriz Araujo Medeiros
Anna Beatriz Araujo Medeiros
SRSandra Rodrigues-Mascarenhas
Sandra Rodrigues-Mascarenhas
Inflammatory bowel disease (IBD) is a chronic condition that significantly impairs the quality of life of millions of individuals. The pathogenesis of IBD is closely linked to dysbiosis of microbiota and the activation of various inflammatory pathways, which are characterized by elevated levels of activated immune cells, such as neutrophils and lymphocytes. While several therapeutic options, including corticosteroids and biologic agents, are available for the treatment of IBD, their efficacy remains limited. Consequently, the development of novel therapies is essential. In this context, cardiotonic steroids, a class of drugs traditionally known for their effects on the cardiovascular system, have gained attention due to their potential immunomodulatory properties. Thus, this review aims to explore the emerging therapeutic potential of cardiotonic steroids in the treatment of IBD.